Omeros (OMER)
(Delayed Data from NSDQ)
$3.98 USD
+0.17 (4.46%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $3.98 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 321 - 340 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of November
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS302 Second Ph3 Positive; With NDA Filing in H1:13, We See Approval in Late ''13-14; We See Buying Opportunity In Front Of OMS103HP Ph3 Data By YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q4 Catalysts Timing Update--We Now Estimate OMS302 Phase 3 Top Line Data Release in early November Followed By OMS103HP Before Year-End.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of October 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Lead PDE-10 Treatment Candidate OMS824 for Potential Blockbuster Indications of Schizophrenia and Cognitive Diseases Going Into the Clinic
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
NIMH Grant Provides Non-Dilutive Funding To Develop GPCR Antibody Treatments For Neurological Diseases; Reiterate OUTPERFORM and $19 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
September and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Life Sciences MAC Best Ideas Conference - New York City - August 14 & 15, 2012 Day 1 Key Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS103HP Phase 3 Trial Completes Patient Enrollment; On Track For Major Catalyst With H2 Data Release; Reiterate OUTPERFORM and $19 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q2 Financials a Non-Event. We Project Cash Runway Well Through Transformational H2 Catalysts. Reiterate OUTPERFORM and $19 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Omeros Makes Important Discovery in MASP-2 Program Which Could Lead to Improved Therapies for Inflammatory Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We are terminating coverage of Omeros Corp due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals - July and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We are placing Omeros Corp under review due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
We Calculate Follow-On Offering Extends Cash Runway Into 2013; Maintaining OUTPERFORM but Reducing FV to $18 For Dilution
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We Calculate Follow-On Offering Extends Cash Runway Into 2013; Maintaining OUTPERFORM but Reducing FV to $18 For Dilution
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L